Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.

MidAtlantic Retina90 enrolled

Overview

You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.

The hypothesis tested here is that diabetic patients that express the higher molecular weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1) level and, as a result, are at a greater risk for the development of more severe diabetic retinopathy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diabetes Diabetes Mellitus

Interventions

Blood drawBIOLOGICAL

3-4 tablespoons of blood will be drawn, one time.

Eligibility

Sex: ALLMin age: 18 Minutes

Medical Language ↔ Plain English

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Diabetes Mellitus * Undergoing pars plana vitrectomy for any reason Exclusion Criteria: * Use of any anti-VEGF (vascular endothelial growth factor ) medications

Locations (1)

Mid Atlantic Retina- Wills Eye Institute

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma

Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.

Time frame: up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.